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Background: Because of the limited number of subjects in prelicensure 
studies, autoimmune diseases and other rare adverse effects of vaccines may 
go undetected. Since 2006, millions of human papillomavirus (HPV) vac-
cine doses have been distributed and a considerable amount of postlicensure 
safety data has been generated. The objective of this study was to review 
available HPV postlicensure safety studies and to summarize risk estimates 
of autoimmune and other rare diseases.
Methods: For this systematic review and meta-analysis, we searched lit-
erature databases to identify any postlicensure safety studies related to 
HPV vaccination and autoimmune adverse events from inception to April 
16, 2019. Pooled risk estimates were computed using fixed- or random-
effects models if at least 2 estimates per disease and per HPV vaccine 
were available.
Results: Twenty-two studies met our inclusion criteria. The studies applied 
various methodologies and used different types of data sources and out-
come definitions. Quadrivalent HPV vaccine (4vHPV) was most commonly 
assessed. Type 1 diabetes mellitus, immune thrombocytopenia purpura and 
thyroiditis diseases were most frequently reported. The meta-analysis was 
conducted on 35 diseases corresponding to 48 pooled risk estimates. Major-
ity of the pooled estimates showed no significant effect (n = 43). Three 
negative (paralysis, immune thrombocytopenia purpura and chronic fatigue 
syndrome) and 2 positive (Hashimoto and Raynaud diseases) associations 
were detected.
Conclusion: Our study demonstrated an absence of clear association 
between HPV vaccines and autoimmune and other rare diseases. The review 
also highlights the need for more systematic collaborations to monitor rare 
safety adverse events.
Key Words: papillomavirus vaccines, autoimmune diseases, rare adverse 
events, postlicensure studies
(Pediatr Infect Dis J 2020;39:287–293)
Human papillomavirus (HPV) vaccines are effective in reducing HPV infections1,2 and in preventing cervical cancer, caused by 
certain HPV genotypes.3 Currently 3 licensed HPV vaccines are 
available: a quadrivalent HPV vaccine (4vHPV; Gardasil, Merck, 
USA) and a bivalent HPV vaccine (2vHPV; Cervarix, GSK, Bel-
gium) licensed in 2006 and 2007, respectively, followed in late 
2014 by 9-valent HPV vaccine (9vHPV; Gardasil9, Merck, USA). 
Table 1 summarizes the characteristics of the 3 vaccines. All 3 HPV 
vaccines were initially licensed and marketed using a 3-dose vac-
cination schedule. However, a 2-dose schedule was subsequently 
approved for all 3 vaccines. HPV vaccines are available in more 
than 100 countries,4 and over 80 countries have included the HPV 
vaccine into their national immunization programs mainly targeting 
young adolescent girls.5 As of 2014, it is estimated that 59 mil-
lion women have received at least 1 dose of HPV vaccine.6 Routine 
vaccination of boys is currently implemented in several countries 
worldwide.
To enhance the immune response, HPV vaccines contain 
adjuvanted systems, such as toll-like receptors or oil-based emul-
sions. These adjuvant vaccines enhance a general immune response 
and may potentially trigger autoimmune reactions (responses 
against body’s own tissue).7 The safety of vaccines and its adjuvants 
require assessment pre licensure and continuous monitoring post 
licensure. This is done by passive surveillance of case reports and 
active surveillance studies, aiming to detect rare reactions or asso-
ciations with diseases that have low incidences. As part of postmar-
keting commitments and requests, several studies were conducted 
aiming to estimate the risks of developing autoimmune diseases 
following HPV vaccination.8,9 To date, available meta-analysis of 
HPV vaccine and autoimmune diseases have largely synthesized 
results of clinical trials10 or a mix of postlicensure studies and clini-
cal trials.11 To address the need to analyze available postlicensure 
safety data, we carried out a systematic review of postlicensure 
observational safety studies assessing the risk of autoimmune and 
rare adverse events following HPV vaccination; we describe the 
methodologic approaches used and we summarize the risk esti-
mates.
MATERIALS AND METHODS
We used a comprehensive 3-step search strategy to iden-
tify relevant studies. No language restrictions were placed on the 
searches or search results. The study conforms to the Preferred 
Reporting Items for Systematic reviews and Meta-analysis guide-
lines12 and European Network of Centres for Pharmacoepidemiol-
ogy and Pharmacovigilance13 (ENCePP) guidelines.
Search Strategy and Selection Criteria
First, we searched Embase.com, Medline (Ovid), ISI Web of 
Science and Cochrane Central from inception to April 16, 2019, for 
any postlicensure observational safety studies assessing the risk of 
autoimmune adverse events following HPV vaccination. A search 
strategy was developed for each database with a combination of free 
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text and controlled vocabulary (ie, medical subject headings terms). 
Additional search terms were included in consultation with a refer-
ence librarian (WB). The detailed search strategies for each database 
are presented in Table, Supplemental Digital Content 1, http://links.
lww.com/INF/D738. Second, we screened reference lists of publi-
cations retrieved to identify additional relevant studies. Third, we 
searched web-based platforms including the EnCePP register14 and 
manual searches in health authorities’ websites and Google Scholar.
Two reviewers (CW, KG) independently screened titles and 
abstracts followed by the retrieval and reviewed full-text articles 
according to the predefined eligibility criteria described below. 
Disagreements were resolved through discussion. The following 
inclusion criteria were applied: (1) HPV vaccination; (2) postli-
censure studies; (3) epidemiologic or Phase IV studies; (4) healthy 
population and (5) risk/safety assessment. Commentaries, meeting 
reports, letters to editors, case reports, biologic or animal studies 
were excluded. Eligible papers, as well as papers which could not be 
excluded right away, were then included in the full-text assessment. 
Selected papers were assessed by reviewing the full-text according 
to the following inclusion criteria: (1) HPV-related adverse events, 
(2) autoimmune diseases and rare safety outcomes assessment, (3) 
no assessment using spontaneous reporting database.
Data Abstraction and Quality Assessment
For each of the eligible studies, we extracted the follow-
ing data as a minimum: first author and year of publication, study 
design, objective and period, data source, geographical area, age 
of subjects, type of vaccine, adverse events reported either as indi-
vidual or composite endpoints, method for identification and vali-
dation of cases, disease onset, risk window and risk estimates.
The study quality was assessed by the 2 same reviewers using 
an adapted quality checklist combining the Newcastle–Ottawa Scale15 
and the Scottish Intercollegiate Guidelines Network16 quality crite-
ria for cohort and case-control studies. The adapted quality check-
list, including assessment of case-only design, is presented in Table, 
Supplemental Digital Content 2, http://links.lww.com/INF/D739. To 
assess the quality of the studies, we scored each of the studies follow-
ing 4 parameters: the selection of study groups (2 points), confound-
ing factors (1 point), assessment of the outcome (3 points) and assess-
ment of the exposure (1 point). The total score represented the sum of 
scores for each parameter. This score was used as a relative measure 
of data quality; no threshold for exclusion was applied.
Data Analysis
Pooled risk estimates (odds ratios, ORs) and their respective 
95% confidence intervals (CIs) for individual autoimmune diseases 
were calculated if at least 2 risk estimates per outcome and per HPV 
vaccine type were available. Under the rare disease assumption, the 
OR and relative risk (RR) can be treated as approximately equal. 
Therefore, the pooled estimate was computed by pooling any risk 
estimates, independently of the type of risk measurement (relative 
risk, OR or hazard ratio) and by using fixed-effects model (Mantel-
Haenszel method) or random-effects model (Der Simonian-Laird 
method). To determine the extent of variation between studies, we 
computed heterogeneity tests with Higgins I2 statistic to measure 
the proportion of observed variance that reflects true effect sizes. I2 
values over 50% were considered as relevant inconsistency between 
studies. Statistical analyses were performed using Stata software.17
RESULTS
Of the 3281 papers, 180 potentially relevant full-text articles 
were independently reviewed. From these, 22 studies (<1%) were 
identified as relevant for our review. Figure 1 depicts the Preferred 
Reporting Items for Systematic reviews and Meta-analysis flow-
chart. Consultation of the ENCePP register and other websites did 
not identify additional studies of interest.
Table, Supplemental Digital Content 3, http://links.lww.com/
INF/D740 shows the main characteristics of the 22 postlicensure 
observational studies meeting the inclusion criteria. Studies were 
published from 2012 to 2019. Fourteen studies were conducted in 
Europe [Denmark and Sweden (5), Finland (1), France (3), Nor-
way (1), the Netherlands (1) and UK (3)] and 8 in North America 
[Canada (2) and USA (6)]. Most studies used a retrospective study 
design and a variety of types of data sources: registers in Nordic 
countries, general practitioners and hospital databases in UK and 
Canada, and claims databases in France and USA. Two prospective 
studies were conducted in France by using the Pharmacoepidemio-
logic General Research Extension methodology, a research platform 
recruiting prospectively and routinely autoimmune disorder cases 
through a network of specialists. Most studies included females 
only with ages ranging from 9 to 44 years, 1 study included males 
only, and 2 studies included males and females of any age. Vari-
ous types of study designs were implemented to assess the risk of 
autoimmune diseases after HPV vaccination; 3 case-control studies 
including 1 matched,18 1 unmatched19 and 1 nested case-control20; 
7 case-only designs including 5 self-controlled case series21–25 and 
2 case-centered method26,27; and 12 cohort studies8,9,28–37 including 
a surveillance study.8 More than 60 different autoimmune and rare 
adverse events were studied. Some studies focused on any auto-
immune diseases (n = 4),28,31,32,35 others (n = 18)8,9,18–27,29,30,33,34,36,37 
targeted specific outcomes. Type 1 diabetes mellitus was the most 
frequently studied (in 11 studies).8,9,18,19,24,28,31–33,35,37 Autoimmune 
TABLE 1. Characteristics of HPV Vaccines






Recommended route of administration Intramuscular Intramuscular Intramuscular
Characteristics by 
dose (0.5 mL)
Formulation Suspension Suspension Suspension
L1 virus-like particle  
types
HPV-16 (20 µg), 18 (20 µg) HPV-6 (20 µg), 11 (40 µg), 16  
(40 µg), 18 (20 µg)
HPV-6 (30 µg), 11 (40 µg), 16 
(60 µg), 18 (40 µg), 31 (20 µg), 
33 (20 µg), 45 (20 µg), 52 (20 
µg), 58 (20 µg)
Cross-protection HPV-31, HPV-33, HPV-45 HPV-31 None
Adjuvant Adsorbed on aluminum hydroxide, 
hydrated (Al(OH)3) (0.5 mg) Al3+ 
in total
Adjuvanted by AS04 containing: 
3--desacyl-4'-MPL (50 µg)
Adsorbed on amorphous alu-
minum hydroxyphosphate 
sulfate adjuvant (0.225 mg Al)
Adsorbed on amorphous alu-
minum hydroxyphosphate 
sulfate adjuvant (0.5 mg Al)
Expression system Baculovirus-insect cell Yeast cells Yeast cells
MPL, monophosphoryl lipid A.
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thyroiditis diseases8,9,19,24,28,32,35,37 including Hashimoto and Grave 
diseases, hypothyroidism and other hyperthyroidism, and immune 
thrombocytopenia purpura8,9,18,19,24,28,32,35 (ITP) were assessed in 8 
studies: Crohn disease21,24,28,32,35,37 in 6 studies, Bell palsy,24,28,31,32,35 
coeliac disease,9,28,31,32,35 juvenile rheumatoid arthritis,8,9,24,35 optic 
neuritis,8,24,27,28,36 rheumatoid arthritis,8,9,28,31,32 ulcerative coli-
tis24,28,31,32,35 and systemic lupus erythematosus8,9,28,32,35 in 5 studies; 
acute disseminated encephalomyelitis,8,20,24,26 chronic fatigue syn-
drome,22,25,30,35 epilepsy,28,31,32,35 Henoch–Schonlein purpura,28,31,32,35 
pancreatitis,9,28,32,35 paralysis,28,31,32,35 psoriasis,28,31,32,35 vasculi-
tis,9,28,31,32 venous thrombocytopenia23,28,31,35 and vitiligo28,31,32,35 in 
4 studies; ankylosing spondylitis,28,31,32 erythema nodosum,28,32,35 
hemolytic anemia,8,24,32 multiple sclerosis,8,20,34 myositis,28,32,35 
narcolepsy,28,31,32 Raynaud disease,28,32,35 scleroderma9,28,32 in 3 
studies. Four studies9,19,21,29 among 7 including data on Guillain-
Barre syndrome (GBS) provided risk estimates. Fourteen stud-
ies8,18,20,23,24,26–32,34,36 concerned 4vHPV vaccine exposure, while 4 
studies22,25,35,37 assessed 2vHPV vaccine exposure. Two studies9,21 
provided risk estimates separately for 4vHPV and 2vHPV vaccine 
exposures. Two studies19,33 assessed a combined exposure to both 
2v-and 4vHPV and both 4vHPV and 9vHPV vaccines.
Based on the adapted quality checklist, the 22 studies 
included in this review were considered to have a satisfactory 
methodologic quality. The quality assessment scores for each study 
are reported in Table, Supplemental Digital Content 3, http://links.
lww.com/INF/D740.
Methodologic Approaches
Methodologic considerations of the 22 studies including 
methods for identification and validation of cases, diagnostic cri-
teria, onset of the diseases and analytical parameters are further 
detailed in Table, Supplemental Digital Content 4, http://links.lww.
com/INF/D741.
Definition of Outcome
Five studies8,9,20,27,37 developed complex algorithms combin-
ing diagnosis codes and additional clinical information such as 
medications, laboratory test results and referral to specialists to 
identify cases. Fifteen studies19,21–26,28–36 identifying cases by diag-
nosis codes only implemented a review of all medical charts or 
contacted health-care providers (6 studies).21,24,26,27,33,36 Three stud-
ies,8,20,37 in addition to elaborated algorithms, put in place a case 
ascertainment process with a panel of specialist physicians. In most 
of the studies, the disease onset was the date of the first diagnosis, 
whereas in 2 studies20,37 using case ascertainment process, the crite-
ria of first clinical sign or symptom were used.
FIGURE 1. PRISMA flowchart of the selection procedure. PRISMA indicates Preferred Reporting Items for Systematic reviews 
and Meta-analysis.
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Analytical Parameters
In some studies,18,19,24,34,37 the researchers created composite 
endpoints including multiple disease conditions such as for demy-
elinating diseases, connective tissue disorders or neuroinflamma-
tory diseases. Two studies24,37 analyzed composite endpoints as 
primary objective, while all other studies assessed individual end-
point as their primary objective. Several time frames, most often 
disease-specific, were evaluated in case-control designs ranging 
from 14 days until 3 years before disease onset. In cohort designs, 
the follow-up time varied from 180 days until 10 years after the 
last exposure irrespective of the disease. Case-only study designs 
were usually applied for individual endpoints only. In those stud-
ies, risk windows were defined according to the disease varying 
from 42 days to 1 year after disease onset. Detailed risk windows 
are presented in Table, Supplemental Digital Content 4, http://links.
lww.com/INF/D741.
Risk Estimates
We computed pooled risk estimates for the following cat-
egories of autoimmune diseases: dermatologic (including erythema 
nodosum, psoriasis, scleroderma, systemic lupus erythematosus 
and vitiligo); hematologic (including ITP); gastrointestinal (includ-
ing coeliac, Crohn disease, pancreatitis and ulcerative colitis); mus-
culoskeletal or systemic diseases (including ankylosing spondylitis, 
Henoch–Schonlein purpura, juvenile rheumatoid arthritis, myosi-
tis, rheumatoid arthritis and vasculitis); neurologic (Bell palsy, epi-
lepsy, GBS, chronic fatigue syndrome, narcolepsy and paralysis); 
ophthalmic (optic neuritis); other demyelinating diseases (including 
central nervous system disorders and multiple sclerosis); thyroiditis 
disorders (including Hashimoto, Graves’ disease and other hyper-
thyroidism); other disorders (including Raynaud disease, Sjogren 
syndrome and venous thrombocytopenia) and type 1 diabetes. 
Pooled estimates were computed for 35 disease conditions cor-
responding to 48 pooled estimates. Pooled estimates are reported 
in Table 2. Risk estimates for all autoimmune diseases and other 
rare events are reported in Table, Supplemental Digital Content 5, 
http://links.lww.com/INF/D742. Most of them were computed for 
4vHPV (n = 34) and the remaining for 2vHPV (n = 14). Majority 
of the pooled estimates did not show significant association (n = 
43). Three pooled estimates showed a protective effect for ITP [OR 
= 0.55 (95% CI: 0.34–0.88)] and chronic fatigue syndrome [OR 
= 0.77 (95% CI: 0.62–0.97)] after 2vHPV vaccine and for paraly-
sis [OR = 0.52 (95% CI: 0.55–0.77)] after 4vHPV vaccine. Two 
pooled estimates showed a statistically significant increased risk for 
Hashimoto disease [OR = 1.25 (95% CI: 1.09–1.44)] and Raynaud 
disease [OR = 1.63 (95% CI: 1.21–2.20)] after 4vHPV vaccine.
For diseases reported in a single study, 9 risk estimates 
showed statistically significant associations (Table, Supplemental 
Digital Content 5, http://links.lww.com/INF/D742). Increased risks 
with relatively large 95% CI were observed in males following 
9vHPV for narcolepsy [RR = 3.44 (95% CI: 1.08–11.0)] and viti-
ligo [RR = 4.70 (95% CI: 1.13–19.5)].
DISCUSSION AND CONCLUSIONS
Following large-scale use of HPV vaccines, rare serious 
adverse events have been reported which prompted additional 
investigations.38–40 Further to this, several postlicensure studies 
were conducted to estimate associations between HPV vaccina-
tion and autoimmune and other rare adverse events. The present 
review is to our knowledge the first comprehensive review aim-
ing to describe the methodologic approaches used in HPV vaccine 
postlicensure observational studies. In addition, we aimed to sum-
marize risk estimates of autoimmune and other rare events follow-
ing immunization with HPV from the available evidence. Among 
the 22 postlicensure observational safety studies included, we iden-
tified 2 important elements informing on the validity and robust-
ness of postlicensure studies assessing rare adverse events.
The first element is related to the validity of the clinical out-
comes and determination of onset of disease. In the eligible studies, 
simple to more complex algorithms were developed to identify and 
validate cases of autoimmune diseases. The level of granularity of 
the clinical case definition may generate, if not consistent across 
studies, an important source of heterogeneity restricting direct com-
parison between studies. As an example, 1 study9 broadly defined 
autoimmune thyroiditis diseases including in its definition codes 
for disease of nonautoimmune origin, while other studies8,24,28,32,35 
targeted specific medical conditions such as Hashimoto disease. 
In addition, algorithm-based approach should ensure a high speci-
ficity of the outcome definition and therefore avoid inclusion of 
false-positive subjects. Algorithm-based search only is deemed suf-
ficiently robust to detect acute events such as GBS. However, for 
diseases with insidious onset, such approach may introduce bias on 
the true onset date.
Second important element is related to the analytical param-
eters including risk period, endpoints and sample size. While a long 
and sufficient follow-up time is required for long latency diseases 
to be detected, risk period must be adequately defined to estab-
lish accurate evidence of a causal relationship. Some autoimmune 
events are known to occur within few weeks after vaccine exposure 
such as GBS detected between 6 and 8 weeks after swine flu vac-
cine.41,42 For some other autoimmune diseases, evidence of time to 
disease onset (ie, multiple sclerosis)43 or lag time between onset of 
symptoms and disease diagnosis (ie, rheumatoid arthritis)44 are not 
well clearly established. In such circumstances, risk periods should 
be defined as much as possible using epidemiologic and mechanistic 
evidences or by expert opinion. Sensitivity analyses using different 
risk periods and clustering analyses are complementary methods to 
highlight potential windows of risk. A disease-specific time frame 
should be the preferred approach when different kind of clinical 
events are under assessment. In case-only study design, a washout 
period between risk and control periods should also be preferably 
considered, to avoid misclassification.45 In the studies, sample sizes 
limitations were overcome by creating composite endpoints or by 
combining multiple healthcare databases. With intrinsic limitations 
such as heterogeneity between databases or lack of specificity of 
the outcome of interest, both alternative approaches emphasize the 
need for collaboration to increase sample size and develop common 
clinical definitions. Because of the rarity of autoimmune diseases, 
some of the studies included in our review may not be adequately 
powered to detect a potential increased or decreased risk. This pos-
sible lack of statistical power may suggest an unreliable absence of 
risk. In addition, 2vHPV vaccine was less frequently studied and 
therefore no estimation of risk could be generated for some of the 
diseases.
Our review also provides pooled risk estimates. Pooled find-
ings in females suggested that 4vHPV vaccination significantly 
increased the risk of both Hashimoto and Raynaud diseases. The 
slightly elevated risk of Hashimoto disease was mainly driven by 
the Chao et al8 study. After further evaluation, the researchers dem-
onstrated that most of the new onset cases were likely preexisting 
cases and that no consistent evidence for a safety signal for auto-
immune thyroid conditions in general was observed among vac-
cinated subjects. Similarly, the increased risk of Raynaud disease 
was driven by the Arnheim-Dahlström et al28 study. The research-
ers discriminated this safety signal based on prespecified causality 
criteria including the strength of the association (rate ratio < 3.0). 
On the contrary, a protective effect was observed for paralysis after 
4vHPV and for ITP and chronic fatigue syndrome after 2vHPV. By 
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using criteria such as the strength of the association, the consist-
ency of the reported risks and the level of significance to interpret 
the risk estimates, we noticed a lack of clear association for all pro-
tective and risk effects with regard to HPV vaccines. In addition, 
the pooled analysis has several limitations due to heterogeneity of 
clinical definitions, targeted age categories and variation in risk 
periods across studies. Two studies28,32 conducted in Sweden and 
Denmark used same sources of data but targeted 2 different age 
categories (10–17 and 18–44 years old). Therefore, the pooled esti-
mate for Raynaud disease and paralysis does not bring any added 
TABLE 2. Summary of Pooled Estimates (ORs) for 35 Autoimmune Diseases 
and/or Other Rare Adverse Events
Outcomes
HPV Vaccine  
Exposure
Pooled Estimates*  
[OR (95% CI)]
I2 Statistics  
(%)
Dermatologic
  Erythema nodosum 4vHPV 1.26 (0.89; 1.79) 0.0
  Psoriasis 4vHPV 1.03 (0.87; 1.23) 0.0
  Scleroderma 4vHPV 1.04 (0.64; 1.69) 29.7
  Systemic lupus erythematosus 4vHPV 1.04 (0.82; 1.33) 0.0
2vHPV 1.20 (0.39; 3.68) 20.5
  Vitiligo 4vHPV 1.31 (0.91; 1.87) 25.6
Diabetes
  Diabetes type 1 diabetes mellitus 4vHPV 0.93 (0.65; 1.34) 86.5
2vHPV 0.80 (0.50; 1.26) 58.5
Hematologic
  Idiopathic thrombocytopenia purpura 4vHPV 1.06 (0.85; 1.33) 40.2
2vHPV 0.55 (0.34; 0.88) 0.0
Gastrointestinal
  Coeliac disease 4vHPV 1.16 (0.87; 1.56) 67.3
2vHPV 1.05 (0.80; 1.38) 0.0
  Crohn disease 4vHPV 1.04 (0.73; 1.47) 69.3
2vHPV 1.17 (0.77; 1.78) 0.0
  Pancreatitis 4vHPV 0.87 (0.69; 1.08) 0.0
2vHPV 1.68 (0.85; 3.33) 0.0
  Ulcerative colitis 4vHPV 0.93 (0.58; 1.50) 80.7
2vHPV 0.57 (0.15; 2.23) 80.7
Musculoskeletal/systemic
  Ankylosing spondylitis 4vHPV 0.98 (0.65; 1.48) 0.0
  Behcet syndrome 4vHPV 1.52 (0.29; 7.96) 69.4
  Henoch–Schonlein purpura 4vHPV 1.03 (0.66; 1.60) 0.0
  Juvenile rheumatoid arthritis 4vHPV 0.73 (0.36; 1.47) 77.7
2vHPV 1.03 (0.82; 1.29) 6.2
  Myositis 4vHPV 0.92 (0.50; 1.69) 0.0
  Polymyositis/dermatomyositis 4vHPV 0.83 (0.46; 1.51) 0.0
  Rheumatoid arthritis 4vHPV 0.92 (0.72; 1.17) 0.0
  Vasculitis 4vHPV 1.11 (0.86; 1.42) 0.0
Neurologic
  Bell palsy 4vHPV 0.79 (0.46; 1.35) 73.8
2vHPV 1.37 (0.83; 2.26) 0.0
  Epilepsy 4vHPV 0.81 (0.54; 1.24) 87.7
  Guillain-Barre syndrome 4vHPV 1.79 (0.65; 4.94) 64.0
2vHPV 2.89 (0.58; 14.40) 69.7
  Chronic fatigue syndrome 2vHPV 0.77 (0.62; 0.97) 11.5
  Narcolepsy 4vHPV 1.08 (0.64; 1.84) 19.3
  Paralysis 4vHPV 0.52 (0.35; 0.77) 0.0
Ophthalmic
  Optic neuritis 4vHPV 1.20 (0.84; 1.71) 19.8
Other demyelinating diseases
  Central nervous system demyelinating 
syndrome
4vHPV 1.02 (0.77; 1.33) 0.0
Multiple sclerosis 4vHPV 0.96 (0.77; 1.21) 0.0
Other disorders
  Raynaud disease 4vHPV 1.63 (1.21; 2.20) 0.0
  Sjogren syndrome 4vHPV 1.34 (0.71; 2.51) 0.0
  Venous thrombocytopenia 4vHPV 0.80 (0.60; 1.07) 0.0
Thyroid
  Hashimoto disease 4vHPV 1.25 (1.09; 1.44) 0.0
2vHPV 0.88 (0.57; 1.36) 0.0
  Grave disease 4vHPV 0.88 (0.73; 1.07) 3.7
2vHPV 1.12 (0.56; 2.24) 63.3
  Autoimmune thyroiditis 4vHPV 1.10 (0.94; 1.27) 0.0
2vHPV 1.76 (0.65; 4.77) 83.3
  Other hyperthyroidism 4vHPV 0.98 (0.79; 1.22) 0.0
Bold estimates are statistically significant.*Pooled estimates were computed using fixed-effects model or random-
effects model (I2 > 50%) in Stata v14.0.
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value and only the individual studies can confirm the observed 
risks. Similarly, a higher risk of Hashimoto disease was observed 
from a pool of 3 studies for which the age of the populations did 
not necessarily overlap. Moreover, the small number of studies 
included in our analysis did not allow stratification by type of study 
design or risk estimates. The pooling of any risk estimates did not 
affect drastically the pooled estimates because for rare events OR 
and relative risk are virtually similar. However, while each indi-
vidual study was fit-for-purpose for the stated objectives, the vari-
ability of methods across studies may impact the ability to validly 
characterize risks. The risk evaluation in our review should be con-
sidered as an indicator of possible harms after HPV vaccination for 
which enhanced and continuous surveillance should be maintained 
or implemented. A recently published meta-analysis11 also showed 
a small increased risk of Hashimoto disease after HPV vaccination. 
However, the authors did not provide analysis by type of HPV vac-
cine. Because the mechanisms of action of adjuvant systems may 
perform differently, a critical evaluation by type of vaccine may 
help to discriminate any potential triggering effect.
This review also underlines the need for harmonization of 
outcome definitions and collaboration in assessing vaccine safety, 
which is one of the efforts currently done in the ADVANCE pro-
ject46 in the European Union and was possible globally for assess-
ing safety of the pandemic influenza vaccine.47
In conclusion, this systematic review emphasizes the diver-
sity of methodologic approaches to assess the risk of developing 
rare adverse events after HPV vaccination. Results show that many 
events have been studied but not systematically for the different 
HPV vaccines. The review highlights that positive and negative 
associations were observed with autoimmune diseases. However, 
these estimates should be interpreted with caution due to the diver-
sity in methodologic approaches used by the studies included in 
this review. More systematic collaborations and harmonization of 
event clinical definitions are needed to monitor rare safety events.
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